Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Accuracy of the new rapid test for monitoring adalimumab levels.
Rocha C, Afonso J, Lago P, Arroja B, Vieira AI, Dias CC, Magro F. Rocha C, et al. Among authors: vieira ai. Therap Adv Gastroenterol. 2019 Feb 27;12:1756284819828238. doi: 10.1177/1756284819828238. eCollection 2019. Therap Adv Gastroenterol. 2019. PMID: 30833984 Free PMC article.
Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays.
Afonso J, Lopes S, Gonçalves R, Caldeira P, Lago P, Tavares de Sousa H, Ramos J, Gonçalves AR, Ministro P, Rosa I, Vieira AI, Coelho R, Tavares P, Soares J, Sousa AL, Carvalho D, Sousa P, da Silva JP, Meira T, Silva Ferreira F, Dias CC, Chowers Y, Ben-Horin S, Magro F; on behalf Portuguese IBD Study Group (GEDII). Afonso J, et al. Among authors: vieira ai. Therap Adv Gastroenterol. 2016 Nov;9(6):781-794. doi: 10.1177/1756283X16658223. Epub 2016 Jul 26. Therap Adv Gastroenterol. 2016. PMID: 27803733 Free PMC article.
Clinical performance of an infliximab rapid quantification assay.
Magro F, Afonso J, Lopes S, Coelho R, Gonçalves R, Caldeira P, Lago P, de Sousa HT, Ramos J, Gonçalves AR, Ministro P, Rosa I, Meira T, Andrade P, Soares JB, Carvalho D, Sousa P, Vieira AI, Lopes J, Dias CC, Geboes K, Carneiro F. Magro F, et al. Among authors: vieira ai. Therap Adv Gastroenterol. 2017 Sep;10(9):651-660. doi: 10.1177/1756283X17722916. Epub 2017 Aug 11. Therap Adv Gastroenterol. 2017. PMID: 28932267 Free PMC article.
Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays.
Afonso J, Lopes S, Gonçalves R, Caldeira P, Lago P, Tavares de Sousa H, Ramos J, Gonçalves AR, Ministro P, Rosa I, Vieira AI, Dias CC, Magro F; Portuguese IBD Study Group (GEDII). Afonso J, et al. Among authors: vieira ai. Aliment Pharmacol Ther. 2016 Oct;44(7):684-92. doi: 10.1111/apt.13757. Epub 2016 Aug 10. Aliment Pharmacol Ther. 2016. PMID: 27507790 Free article.
Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy.
Magro F, Alves C, Lopes J, Lopes S, Tavares de Sousa H, Cotter J, Macedo da Silva V, Lago P, Vieira A, Brito M, Duarte MAM, Portela F, Silva JP, Ministro P, Arroja B, Carvalho L, Torres J, Santiago M, Estevinho MM, Danese S, Peyrin-Biroulet L, Dias CC, Borralho P, Feakins RM, Carneiro F. Magro F, et al. Clin Gastroenterol Hepatol. 2021 Dec;19(12):2567-2576.e9. doi: 10.1016/j.cgh.2020.09.017. Epub 2020 Sep 10. Clin Gastroenterol Hepatol. 2021. PMID: 32920215
Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years.
Magro F, Magalhães D, Patita M, Arroja B, Lago P, Rosa I, Tavares de Sousa H, Ministro P, Mocanu I, Vieira A, Castela J, Moleiro J, Roseira J, Cancela E, Sousa P, Portela F, Correia L, Santiago M, Dias S, Alves C, Afonso J, Danese S, Peyrin-Biroulet L, Dias CC; GEDII. Magro F, et al. Clin Gastroenterol Hepatol. 2022 Sep;20(9):2059-2073.e7. doi: 10.1016/j.cgh.2021.12.004. Epub 2021 Dec 9. Clin Gastroenterol Hepatol. 2022. PMID: 34896644
Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation.
Magro F, Afonso J, Lopes S, Coelho R, Gonçalves R, Caldeira P, Lago P, de Sousa HT, Ramos J, Gonçalves AR, Ministro P, Rosa I, Vieira AI, Andrade P, Soares JB, Carvalho D, Sousa P, Meira T, Lopes J, Moleiro J, Dias CC, Falcão A, Geboes K, Carneiro F; Portuguese IBD Study Group (GEDII). Magro F, et al. Among authors: vieira ai. EBioMedicine. 2017 Jul;21:123-130. doi: 10.1016/j.ebiom.2017.06.004. Epub 2017 Jun 7. EBioMedicine. 2017. PMID: 28629912 Free PMC article.
Development and Validation of Risk Matrices for Crohn's Disease Outcomes in Patients Who Underwent Early Therapeutic Interventions.
Dias CC, Rodrigues PP, Coelho R, Santos PM, Fernandes S, Lago P, Caetano C, Rodrigues Â, Portela F, Oliveira A, Ministro P, Cancela E, Vieira AI, Barosa R, Cotter J, Carvalho P, Cremers I, Trabulo D, Caldeira P, Antunes A, Rosa I, Moleiro J, Peixe P, Herculano R, Gonçalves R, Gonçalves B, Sousa HT, Contente L, Morna H, Lopes S, Magro F; on behalf GEDII. Dias CC, et al. Among authors: vieira ai. J Crohns Colitis. 2017 Apr 1;11(4):445-453. doi: 10.1093/ecco-jcc/jjw171. J Crohns Colitis. 2017. PMID: 27683799
52 results